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NREGULATORY AGENCY ACTION
SB 613 (Calderon). Existing law re-
quires a registered optometrist who tem-
porarily practices optometry outside or
away from his/her regular place of prac-
tice to deliver to each patient there fit-
ted or supplied with glasses a specified
receipt. As amended July 10, this bill
would instead require a registered op-
tometrist to furnish to each patient there
fitted or supplied with prescription spec-
tacle lenses aspecified receipt. This two-
year bill is pending in the Assembly
Health Committee.
AB 1046 (Tucker), as introduced
March 4, adds optometrists to the list of
individuals required to report any evi-
dence of abuse of an elderly or depen-
dent person. This bill was signed by the
Governor on July 27 (Chapter 197, Stat-
utes of 1991).
RECENT MEETINGS:
At its August meeting, the Board
discussed the status of its consumer edu-
cation pamphlet, which was turned over
to the Administration Committee for
revision because it fails to address con-
sumer concerns and questions that are
received at the Board's office. Execu-
tive Officer Karen Ollinger will draft
recommendations for language that ad-
equately addresses consumer needs.
Also in August, Karen Ollinger an-
nounced that the Board would be hiring
an additional staff member to assist in
processing the backlog of discipline
cases pending at the Board.
FUTURE MEETINGS:
February 20-21 (location un-
decided).
May 29-30 (location undecided).
BOARD OF PHARMACY
Executive Officer: Patricia Harris
(916) 445-5014
Pursuant o Business and Professions
Code section 4000 et seq., the Board of
Pharmacy grants licenses and permits
to pharmacists, pharmacies, drug manu-
facturers, wholesalers and sellers of hy-
podermic needles. It regulates all sales
of dangerous drugs, controlled sub-
stances and poisons. The Board is au-
thorized to adopt regulations, which are
codified in Division 17, Title 16 of the
California Code of Regulations (CCR).
To enforce its regulations, the Board
employs full-time inspectors who in-
vestigate accusations and complaints
received by the Board. Investigations
may be conducted openly or covertly as
the situation demands.
The Board conducts fact-finding and
disciplinary hearings and is authorized
by law to suspend or revoke licenses or
permits for a variety of reasons, includ-
ing professional misconduct and any
acts substantially related to the practice
of pharmacy.
The Board consists of ten members,
three of whom are public. The remain-
ing members are pharmacists, five of
whom must be active practitioners. All
are appointed for four-year terms.
MAJOR PROJECTS:
Investigation of Fee Agreements
Between Physicians and Home Health
Agencies. For several months, a Board
subcommittee has been investigating
concerns over fee arrangements be-
tween physicians and home health
agencies; last spring, the subcommit-
tee submitted the evidence it had com-
piled and its findings to the Attorney
General's office. (See CRLR Vol. 11,
No. 3 (Summer 1991) p. 101; Vol. 11,
No. 2 (Spring 1991) p. 97; and Vol. 11,
No. 1 (Winter 1991) p. 82 for back-
ground information.)
On July 22, Deputy Attorney Gen-
eral William Marcus replied with a pre-
liminary opinion that such arrangements
("kickbacks") probably violate Business
and Professions Code section 650. In
reaching his conclusion, Marcus evalu-
ated various sample contracts between
physicians and home health agencies
which call for payment from the home
health agency to the physician/pre-
scriber. Marcus noted that the obliga-
tions of the prescriber under most of the
contracts were "simply those which the
primary physician would ordinarily be
expected to provide his or her pa-
tient .. " In other words, "the physi-
cian is being paid by the home health
agency for what he or she is already, as
the patient's physician, obligated to pro-
vide." If this is the case, then the physi-
cian is probably being paid for the refer-
ral, and that is illegal under section 650.
Marcus recommended that the
Board identify and discipline violators
as appropriate, and work with other li-
censing boards to enforce the law
against their licensees. In response, the
Board is considering drafting regula-
tory proposals which would require the
disclosure of contracts between home
health care companies and health care
consultants.
In a related issue, AB 819 (Speier)
and AB 2070 (Isenberg) would amend
section 650 to generally make it un-
lawful for licensed health profes-
sionals to refer a person to any lab-
oratory, pharmacy, clinic, or health care
facility in which the referring party has
an ownership interest. (See infra
LEGISLATION.)
Federal Policy Guide Regarding
New Drug Repacking. In its Compli-
ance Policy Guide 7132c.06, the fed-
eral Food and Drug Administration
(FDA) states that "each step in the manu-
facture and processing of a new drug or
antibiotic, from handling of raw ingre-
dients to final packaging, must be ap-
proved by FDA, whether carried out by
the original manufacturer or by some
subsequent handler or repacker of the
product. Pharmacists are not exempt
from these statutory requirements; how-
ever, the agency regards mixing, pack-
aging, and other manipulations of ap-
proved drug [sic] by licensed
pharmacists, consistent with the ap-
proved labeling of the product, as an
approved use of the product if conducted
within the practice of pharmacy, i.e.,
filling prescriptions for identified pa-
tients." In a July 16 letter from the Board
to the FDA, the Board sought clarifica-
tion as to whether manipulation by a
pharmacy of an FDA-approved drug
constitutes manufacturing (which re-
quires registration as a manufacturer)
when "(1) it is contrary to the
manufacturer's package insert, or (2) it
is prepared for a specific patient in ad-
vance, but in anticipation of, a prescrip-
tion, or (3) it is prepared in anticipation
of receiving one or more prescriptions
for the product, as manipulated, but for
a specific patient." At this writing, the
Board has not yet received a response
from FDA.
Compounding for Office Use. At its
July 31 meeting, the Board continued
the regulatory hearing on proposed sec-
tions 1716.1 and 1716.2, regarding the
definition of the "reasonable quantity
of compounded medication" which a
pharmacist may furnish to a prescriber
for office use under Business and Pro-
fessions Code section 4046(c)(1). (See
CRLR Vol. 11, No. 3 (Summer 1991) p.
102; Vol. 1l, No. 2 (Spring 1991) p. 98;
and Vol. 11, No. 1 (Winter 199 1) p. 8 3
for background information.) Proposed
new section 1716.1 would clarify the
definition of the terms "reasonable quan-
tity," "compounded," and "prescriber
office use" as referenced in Business
and Professions Code section
4046(c)(1). Proposed new section
1716.2 would specify the minimum
types of records that pharmacies must
keep when they furnish compounded
medication to prescribers in quantities
larger than required for the prescriber's
immediate office use or when a phar-
macy compounds medication for future
furnishing.
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At the July meeting, the Board made
minor changes to the proposed language
which, among other things, allows con-
sideration of stability studies when pre-
paring quantities for use over more than
six months, and includes repackaging
in the definition of compounding. The
Board subsequently released the new
language for a 15-day comment period;
comments received were scheduled to
be reviewed at the Board's October
meeting. At that meeting, the Board
planned to finalize the proposed lan-
guage and adopt the regulatory changes,
subject to approval by the Department
of Consumer Affairs and the Office of
Administrative Law (OAL).
Partial Filling of Schedule IH Pre-
scriptions for the Terminally Ill. In Sep-
tember, the Board published notice of
its proposal to adopt section 1745, Title
16 of the CCR. The proposed regula-
tion would permit partial filling of
Schedule II controlled substance pre-
scriptions when (1) the prescription is
at least partially filled within seven days
of the date of issue; (2) the prescription
is for a terminally ill patient; (3) the
patient is in chronic pain; (4) the phar-
macist records the date and amount of
each partial filling in a readily retriev-
able form and on the original triplicate
prescription, and his/her initials; (5) no
portion of the prescription is dispensed
more than 30 days from the date of
issuance of the prescription; and (6) the
original triplicate prescription is for-
warded to the Department of Justice at
the end of the month in which it has
been completely filled or the month in
which the prescription has been can-
celled or discontinued by the death of
the patient.
According to the Board, this pro-
posed regulation is consistent with a
new federal rule, specifically C.F.R.
section 1306.13(b), which took effect
July 3, and would clarify when and how
a pharmacist may partially fill a pre-
scription for Schedule II drugs. The
Board was scheduled to hold a public
hearing on proposed section 1745 on
October 16.
Part-Time Pharmacists-in-Charge.
At its July 31 meeting, the Board dis-
cussed the possibility of amending sec-
tion 1709.1, Title 16 of the CCR, which
governs the designation of the pharma-
cist-in-charge at each pharmacy and pro-
hibits a pharmacist from acting as phar-
macist-in-charge at more than one
pharmacy. The Board has received in-
quiries as to whether this rule prevents a
pharmacist from being the pharmacist-
in-charge at two or more pharmacies
when those pharmacies are open only
part-time and are not open during the
same hours. The Board was scheduled
to resume this discussion at its October
meeting, in anticipation of a formal
amendment proposal.
Regulatory Update. The following
is a status update on regulatory changes
considered and approved by the Board
in recent months (see CRLR Vol. 11,
No. 3 (Summer 1991) pp. 101-02; Vol.
11, No. 2 (Spring 1991) p. 98; and Vol.
11, No. I (Winter 1991) p. 83 for de-
tailed background information on these
changes):
-Continuing Education Advertising.
The Board's revision to section
1732.3(d), pertaining to continuing edu-
cation advertising, was approved by
OAL on July 9.
-Processing Times for Application
and Registrations. New section 1706.1
specifies the time periods within which
the Board will process applications pur-
suant to the Permit Reform Act of 1981,
Government Code section 15374 et seq.
Section 1706.1 was approved by OAL
on July 22.
-Minimum Standards for Drug
Wholesalers. At its May meeting, the
Board adopted proposed amendments
to section 1780, regarding minimum
standards for drug wholesalers, subject
to minor modifications. The modified
language was released for a 15-day com-
ment period commencing on June 18;
no comments were received. At this writ-
ing, the proposed amendments await
review and approval by OAL.
LEGISLATION:
AB 1188 (Speier), as amended May
13, subjects Schedule IV drugs to the
California Uniform Controlled Sub-
stances Act, thus requiring that prescrip-
tions for these drugs have the signature,
date, and other specified information
wholly written in ink or indelible pencil
in the handwriting of the prescriber. This
bill also prohibits a person from refill-
ing a Schedule III or IV prescription in
an amount which exceeds a 120-day
supply. This bill was signed by the Gov-
ernor on October 5 (Chapter 592, Stat-
utes of 1991).
AB 2070 (Isenberg), as amended
August 19, would generally make it un-
lawful for specified healing arts licens-
ees to refer a person to any laboratory,
pharmacy, clinic, or health care facility
solely because the licensee has an own-
ership interest in the facility. However,
a licensee could make those referrals if
the person referred is the licensee's
patient of record, there is no alterna-
tive provider or facility available, and
the licensee certifies that to delay or
forego the referral would cause an un-
needed health risk to the patient. This
two-year bill is pending in the Senate
Rules Committee.
The following is a status update on
bills reported in detail in CRLR Vol. 11,
No. 3 (Summer 1991) at pages 102-03:
AB 1371 (Wright). Existing law con-
tains a variety of provisions regulating
medical device retailers, with which
each retailer must comply on or before
July 1, 1991. As amended June 13, this
bill extends the date for compliance un-
til July 1, 1992 for home health agen-
cies and hospices licensed under speci-
fied provisions. During the one-year
period of exemption, this bill requires
the Board, licensed home health agen-
cies, and licensed hospices to work to-
gether to develop language for legisla-
tion regarding the handling of dangerous
devices by home health agencies and
hospices that proposes safeguards nec-
essary to protect the public health and
that is least restrictive on the function-
ing of home health agencies and hos-
pices. This bill was signed by the Gov-
ernor on July 29 (Chapter 253, Statutes
of 1991).
AB 1253 (Baker), as amended April
29, permits the Board to waive any re-
quirement of licensure for pharmacies,
hospital pharmacies, and medical de-
vice retailers if specified conditions are
met. This bill also provides that existing
regulations do not prohibit the storage
of medical devices in secure central or
ward supply areas of specified estab-
lishments. This bill was signed by the
Governor on October 5 (Chapter 594,
Statutes of 1991 ).
AB 1893 (Lancaster), as amended
August 19, revises the applicability of
pharmacy laws with respect to certain
medical supplies; retitles the Impaired
Pharmacist Program, scheduled for re-
peal on January 1, 1992, as the "Phar-
macist Recovery Program" and contin-
ues its provisions indefinitely; and
extends indefinitely provisions of exist-
ing law which authorize the Board, un-
til January 1, 1992, to deny, revoke, or
suspend a nonresident pharmacy regis-
tration for conduct which causes seri-
ous bodily or psychological injury to a
resident of this state, subject o speci-:
fied conditions. This bill was signed by
the Governor on October 7 (Chapter
654, Statutes of 1991).
AB 1244 (Polanco) permits a phar-
macy technician, as defined, to perform
packaging, manipulative, repetitive, or
other nondiscretionary tasks while as-
sisting, and while under the direct su-
pervision of, a registered pharmacist.
As amended August 19, this bill re-
quires such technicians to be registered
with and certified by the Board, with
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specified exceptions. This bill was
signed by the Governor on October 11
(Chapter 841, Statutes of 1991).
AB 1675 (Margolin), as introduced
July 18, would have required the Board
to designate a statewide drug informa-
tion center for the purpose of offering
direct telephone assistance or referral to
health care providers for any person
desiring information relating to prescrip-
tion drugs. The bill would have required
the Board to provide on license renewal
forms an opportunity to make voluntary
contributions to the statewide drug in-
formation center. This bill was vetoed
by the Governor on October 13.
SB 594 (Roberti), as amended July
18, would have required the State De-
partment of Alcohol and Drug Programs
and the Department of Aging to jointly
administer a statewide roundtable to
develop a consistent, long-term medi-
cation education program model for eld-
erly consumers. This bill was vetoed by
the Governor on October 9.
SB 664 (Calderon), as introduced
March 5, would prohibit pharmacists,
among others, from charging, billing,
or otherwise soliciting payment from
any patient, client, customer, or third-
party payor for any clinical laboratory
test or service if the test or service was
not actually rendered by that person or
under his/her direct supervision, ex-
cept as specified. This bill is pending
in the Senate Business and Professions
Committee.
AB 1226 (Hunter), as introduced
March 6, would change the standard to
be applied by the Director of the De-
partment of Health Services in estab-
lishing a formulary of generic drug types
and drug products, to require him/her to
identify those generic drug types and
drug products which, if substituted by a
pharmacist for a drug product described
by the prescriber by its trade or brand
name, may pose a threat to the health
and safety of patients. This bill is pend-
ing in the Assembly Health Committee.
SB 1033 (Marks), as introduced
March 8, would permit pharmacists to
manufacture, measure, fit to the patient,
sell, and repair medical devices without
regard to whether they bear a specified
legend relating to a federal prohibition
against dispensing without a prescrip-
tion. This bill is pending in the Senate
Business and Professions Committee.
AB 855 (Hunter), as amended July
16, would require a pharmacist to ob-
tain a patient's consent prior to filling a
prescription order for a drug product
prescribed by its trade or brand name
with a substitute drug product. This two-
year bill is pending in the Senate Busi-
ness and Professions Committee.
SB 917 (Kopp), as amended June 11,
would require certain health care ser-
vice plans that propose to offer a phar-
macy benefit or change its relationship
with pharmacy providers to give writ-
ten or published notice to pharmacy ser-
vice providers of the plan's proposal,
and give those providers an opportunity
to submit a bid to participate in the
plan's panel of providers on the terms
proposed. This bill is pending at the
Assembly desk.
AB 819 (Speier). Existing law pro-
vides that it is not unlawful for pre-
scribed licensed health professionals to
refer a person to a laboratory, pharmacy,
clinic, or health care facility solely be-
cause the licensee has a proprietary in-
terest or coownership in the facility. As
introduced February 27, this bill would
instead provide that, subject to speci-
fied exceptions, it is unlawful for these
licensed health professionals to refer a
person to any laboratory, pharmacy,
clinic, or health care facility which is
owned in whole or in part by the lic-
ensee or in which the licensee has a
proprietary interest; the bill would also
provide that disclosure of the owner-
ship or proprietary interest does not ex-
empt the licensee from the prohibition.
This bill is pending in the Assembly
Health Committee.
RECENT MEETINGS:
At the Board's July 31 meeting, staff
reported that a budget change proposal
to create a toll-free telephone number
for consumer inquiries has been post-
poned until the 1993-94 fiscal year. (See
CRLR Vol. 11, No. 3 (Summer 1991) p.
103 for background information.) The
postponement was attributed to the need
to concentrate funding on the Board's
enforcement backlog.
FUTURE MEETINGS:
January 22-23 in Sacramento.
March 18-19 in San Diego.
May 27-28 in Sacramento.
BOARD OF REGISTRATION FOR
PROFESSIONAL ENGINEERS
AND LAND SURVEYORS
Executive Officer: Darlene Stroup
(916) 920-7466
The Board of Registration for Pro-
fessional Engineers and Land Survey-
ors (PELS) regulates the practice of en-
gineering and land surveying through
its administration of the Professional
Engineers Act, sections 6700 through
6799 of the Business and Professions
Code, and the Professional Land Sur-
veyors' Act, sections 8700 through 8805
of the Business and Professions Code.
The Board's regulations are found in
Division 5, Title 16 of the California
Code of Regulations (CCR).
The basic functions of the Board are
to conduct examinations, issue certifi-
cates, registrations, and/or licenses, and
appropriately channel complaints
against registrants/licensees. The Board
is additionally empowered to suspend
or revoke registrations/licenses. The
Board considers the proposed decisions
of administrative law judges who hear
appeals of applicants who are denied a
registration/license, and those who have
had their registration/license suspended
or revoked for violations.
The Board consists of thirteen mem-
bers: seven public members, one li-
censed land surveyor, four registered
Practice Act engineers and one Title Act
engineer. Eleven of the members are
appointed by the Governor for four-
year terms which expire on a staggered
basis. One public member is appointed
by the Speaker of the Assembly and one
by the Senate President pro Tempore.
The Board has established four stand-
ing committees and appoints other spe-
cial committees as needed. The four
standing committees are Administration,
Enforcement, Examination/Qualifica-
tions, and Legislation. The committees
function in an advisory capacity unless
specifically authorized to make binding
decisions by the Board.
Professional engineers are registered
through the three Practice Act catego-
ries of civil, electrical, and mechanical
engineering under section 6730 of the
Business and Professions Code. The
Title Act categories of agricultural,
chemical, control system, corrosion, fire
protection, industrial, manufacturing,
metallurgical, nuclear, petroleum, lual-
ity, safety, and traffic engineering are
registered under section 6732 of the
Business and Professions Code.
Structural engineering and
geotechnical engineering are authori-
ties linked to the civil Practice Act and
require an additional examination after
qualification as a civil engineer.
MAJOR PROJECTS:
Rulemaking Update. At its August 2
meeting, the Board discussed proposed
changes to section 472, Division 5, Title
16 of the CCR (fines for citations against
a professional engineer or land sur-
veyor). (See CRLR Vol. 11, No. 3 (Sum-
mer 1991) p. 104 and Vol. 11, No. 2
(Spring 1991) pp. 100-01 for back-
ground information.) The proposed sec-
tion would authorize the Board to im-
pose fines up to $2,500 and lists seven
factors the Executive Officer should
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